

Research Article

***Citrus sinensis*: Antithrombotic potential and safety concerns involving possible interactions based on in vitro coagulometric tests**

Paula Mendonça Leite¹, Ana Paula Nader Miranda¹, Juliana Mendes Amorim¹, Rita Carolina Figueiredo Duarte², André Augusto Gomes Faraco¹, Maria das Graças Carvalho², Rachel Oliveira Castilho^{1,*}

¹ Department of Pharmaceutical Products, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Av. Antônio Carlos 6627, Belo Horizonte, Minas Gerais, Brazil

² Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Av. Antônio Carlos 6627, Belo Horizonte, Minas Gerais, Brazil

ARTICLE INFO

Keywords:

Anticoagulants
Herbal medicine
Citrus
Thrombin
generation
Warfarin

ABSTRACT

Background: *Citrus sinensis*, popularly called sweet orange, is widely used in Brazil for its calming properties, particularly in treating anxiety and insomnia, even among patients using warfarin. However, there is no scientific data supporting the safe concurrent use of both. **Objective:** To access the in vitro activity of *C. sinensis* ethanolic extract (EtEXT) and its fractions on blood clotting. **Methods:** The study used activated partial thromboplastin time (aPTT), prothrombin time (PT) and plasma fibrinogen measurement (PF), and thrombin generation test (TGT) to evaluate the effects. TGT, a highly sensitive assay, investigates overall changes in the hemostatic system and can evaluate the qualitative micromolecular chemistry of *C. sinensis* EtEXT and its fractions. **Results:** The EtEXTs of sweet orange leaves and their fractions were added to plasma pools at concentrations of 1.67 mg/ml, 2.26 mg/ml, and 2.86 mg/ml. Presence of phenolics as coumarins, flavonoids and tannins, as well as triterpenes was confirmed. At all concentrations, the extract increased PT and aPTT while decreasing PF and TGT, except for the hexane fraction. **Conclusion:** Our findings provide scientific evidence supporting both patient care in the context of warfarin use and the potential development of new antithrombotics. The leaves of sweet orange exhibited in vitro anticoagulant effects, likely due to interference in both extrinsic (EXT-path) intrinsic (INT-path) coagulation pathways. The function of the identified substances in these effects was also discussed, as well as the potential for using this extract in developing antithrombotic agents.

Abbreviations: aPTT, Activated Partial Thromboplastin Time; CS, Citrus Sinensis; DCM, Dichloromethane; EtAc, Ethyl Acetate; EtOH, Ethanolic extract; HEX, Hexane; HTF, High Tissue Factor; LTF, Low Tissue Factor; MG, Minas Gerais; ANOVA, One-Way Analysis Of Variance; PF, Plasma Fibrinogen Measurement; PT, Prothrombin Time; SD, Standard Deviation; SPSS, Statistical Package For The Social Sciences; TLC, Thin Layer Chromatographic; ETP, Thrombin Generation; TGT, Thrombin Generation Test; UPLC-FR-DAD, Ultra Performance Liquid Chromatography; WARF, Warfarin; H2O, Water

*Corresponding author: roc2006@farmacia.ufmg.br

doi: [10.61882/jmp.24.93.53](https://doi.org/10.61882/jmp.24.93.53)

Received 23 September 2024; Received in revised form 13 December 2024; Accepted 17 March 2025

© 2023. Open access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<https://creativecommons.org/licenses/by-nc/4.0/>)

1. Introduction

Citrus genus, within Rutaceae family, encompasses several species of important fruit trees worldwide [1]. This genus, characterized by trees and bushes rich in vitamin C, includes species of significant nutritional and medicinal importance such as *Citrus sinensis*, *C. aurantium*, *C. limon*, *C. paradisi* and *C. reticulata* [1, 2]. *Citrus sinensis* (L.) Osbeck, popularly named sweet orange, represents the greatest citrus cultivar group, being responsible for 70% of the total citrus production. Although native to Asia, this plant has spread extensively in tropical, subtropical, and high-temperature regions [3].

The chemical composition of this species is complex, involving carotenoids, steroids, flavonoids, coumarins, phenylpropanoids, and other volatile compounds [1, 4]. Flavonoids, however, are particularly significant both quantitatively and qualitatively. Examples include flavanones such as hesperidin and naringenin, flavones like apigenin and rutin, and polymethoxylated flavones like nobiletin and tangeretin [4-7] (Supplementary Material 1).

In traditional/popular medicine, *C. sinensis* is applied to stimulate the immune system due to its high vitamin C content, and to treat conditions such as cold, bronchitis, anxiety, stress, constipation, colic, and even hypertension [1]. Experimental evidence has demonstrated pharmacological activities including antioxidant, antilipidemic, cardioprotective, antiproliferative and anticancer effects [3]. This species is one of the most used in Brazil; the tea of *Citrus* leaves is employed as a sedative for insomnia and anxiety [8].

Another study conducted in Brazil indicated that this species was frequently used by patients using warfarin (WARF) with atrial fibrillation diagnosis, in the form of leaf tea [9]. It is known that anticoagulation pharmacotherapy is complex and poses several challenges, including the

potential for interactions with herbs [10-12]. Plants of the genus *Citrus* have already been implicated in interactions with WARF, such as *C. paradisi* (grapefruit) [13-16] and *C. limon* (lemon) [17]. Additionally, the sweet orange fruit has demonstrated in vitro antiplatelet activity [18], indicating a potential interaction with anticoagulants [19, 20].

From this perspective, studying the anticoagulant activity of *C. sinensis* can provide scientific evidence to support its potential interaction with anticoagulants and evaluate its potential as an antithrombotic agent, given its established antioxidant, anti-inflammatory, and antiplatelet activities. This study aimed to investigate the anticoagulant potential of the ethanolic extract (EtEXT) of *C. sinensis* leaves and their fractions through in vitro coagulometric tests, correlating the results with the chemical composition.

2. Methods

2.1. Obtention and preparation of the dried plant

Citrus sinensis was collected in March 2017 in Pará de Minas (MG), Brazil, situated at 19°83'S and 44°60'W, at an elevation of 790 meters. A voucher specimen of *C. sinensis* was botanically identified in the Herbarium of UFMG and deposited with the identification number BHBC 178194.

2.1.1. Elaboration of the Extract

Ethanolic extract (EtEXT) of *Citrus sinensis* was dried and obtained as described by Leite et al., 2019 [19]. It was stored, until use, in a freezer. This extract was employed in coagulometric tests, chromatographic analyses, and fractionation. The fractions of EtEXT were elaborated using liquid-liquid extraction. In the first fractionation, 1 g of the EtEXT was added to 50 mL of water and extracted 3 times with dichloromethane. In the second fractionation, 1 g

of EtEXT was mixed to 50 mL of water and extracted with solvents of increasing polarities: hexane and ethyl acetate. The fractions obtained were biomonitoried by the in vitro TGT assay and analyzed by UPLC-FR-DAD.

2.2. Chemical composition evaluation

The existence of phenolic substances (coumarins, flavonoids, tannins) and sterols/triterpenes was evaluated by thin-layer chromatography (TLC) applying reagents with selectivity for each class of compounds: potassium hydroxide NP/PEG, ferric chloride, and Liebermann-Burchard, respectively [21]. The chromatographic profiles were acquired using ultra-performance liquid chromatography (UPLC) as described in the methods section of Leite et al. (2019) [19].

2.3. Plasma sampling of participants

Recruitment of participants as well as blood collection and processing happened in April 2017. The volunteers individually signed the the form giving free and informed consent, and all ethical guidelines were followed as per the approval of the institution's ethics committee. Participants were healthy women and men; aged 18 years or more; students and professors of the Faculty of Pharmacy, UFMG. They were not users of any drugs with the potential to modify the hemostatic system (e.g., anticoagulants, antiplatelets, non-steroidal anti-inflammatory drugs, and contraceptives). Twelve people were included in the study, as they met the eligibility criteria.

For all tests performed, low-platelet plasma was used. Plasma samples were obtained from the collection of 20 mL of whole blood in tubes containing sodium citrate (0.109 mol/L). These samples were centrifuged at 3000 g for 15 minutes until plasma separation. The 12 samples were mixed in a pool, and aliquots of 2 mL of the

plasma pool (PP) were transferred to microtubes (stored frozen at -80°C). The control was the pure plasma pool, while the test samples included the plasma pool with the addition of the extract.

2.4. Coagulometric Tests

Sample preparation involved the addition of 5 mg of the dried EtEXT to 1 mL (NaCl 0.9%). The ultrasound bath was used for ten minutes to aid in dissolution. Aliquots of these preparations were then mixed in 1 mL of the PP to obtain concentrations of 1.67 mg/mL, 2.26 mg/mL, and 2.86 mg/mL. The control was prepared using the same procedure with NaCl 0.9% replacing the extract. The activity on coagulation was measured by activated partial thromboplastin time (aPTT), prothrombin time (PT), plasma fibrinogen measurement (PF), and thrombin generation test (TGT). The employed methodology can be accessed in Leite et al., 2019 [20]. The intra-assay variation coefficients for PT, aPTT, PF, and TGT were 1.29%, 1.49%, 2.52%, and 0.34%, respectively.

TGT was executed using high tissue factor (HTF) and low tissue factor (LTF), reagents that vary in the amount of tissue factor. For analysis, only the ETP measure was used, representing the thrombin produced during the coagulation process and thus providing better clinical insights. Due to the robustness of TGT, this assay was used to biomonitor the fractionation of the EtEXT of *Citrus sinensis*.

2.5. Ethical issued

All procedures involving human participants were performed following the ethical standards of the institutional research committee (Ethical Committee of Universidade Federal de Minas Gerais, under the number 60904316.6.0000.5149).

2.6. Test statistics

The Statistical Package for the Social Sciences (SPSS), in its 13.0 version, was employed to data analysis. Tables 1-3 contain the experimental data demonstrated as mean \pm standard deviation (SD), and one-way analysis of variance (ANOVA) with post-hoc Tukey HSD was used to evaluate significant differences between the control and the samples considering $P < 0.05$. All experiments were conducted in quadruplicate, yielding consistent results.

The EtEXT of *C. sinensis* showed in vitro anticoagulant activity in all (TGT, aPTT, PT and PF) the coagulometric tests conducted (Tables 1-3). In addition, all fractions obtained in fractionations 1 and 2 were effective in reducing thrombin generation (ETP) in TGT compared to control (Tables 2 and 3). Thrombin generation curves showing the difference in thrombin formation between control and samples of EtEXT of *C. sinensis* (CS) and fractions obtained in the fractionation 2 are shown in Figure 1.

3. Results

3.1. Anticoagulant activity

Table 1. The anticoagulant activity of *C. sinensis* in coagulometric tests: activated partial thromboplastin time (aPTT), prothrombin time (PT) and fibrinogen plasma measurement (PF)

Coagulometric test	Concentration (mg/mL)	Mean	SD	p value
Prothrombin time (PT) (Control = 15.18 ± 0.34 s)	1.67	17.13	0.95	0.000*
	2.26	18.16	0.60	0.000*
	2.86	10.88	0.34	0.000*
Activated partial thromboplastin time (aPTT) (Control= 28.45 ± 0.39 s)	1.67	35.81	2.52	0.000*
	2.26	39.66	1.97	0.000*
	2.86 [†]	40.43	1.32	0.000*
Fibrinogen plasma measurement (PF) (Control= 11.97 ± 1.02 s)	1.67	13.03	0.74	0.415
	2.26 [†]	14.07	0.94	0.015*
	2.86 [†]	14.61	1.49	0.000*

*Significative difference; [†]There is no significant difference between this and the previous concentration tested

Table 2. The anticoagulant activity of *C. sinensis* showed by ETP parameter (calculated as the area under the curve) using high tissue in high concentration as a trigger


Thrombin generation parameters	Tested sample	Concentration (mg/mL)	Mean	SD	p value
Ethanol extract (EtEXT) in different concentrations					
ETP (Control = 1503 ± 61 nM/min)	EtEXT	1.67	712	149	0.000*
	EtEXT	2.26	501	120	0.000*
	EtEXT	2.86	216	214	0.000*
Fractionation 1: water (H₂O) and dichloromethane (DCM)					
ETP (Control = 1678 ± 92 nM/min)	EtEXT	2.26	898	18	0.000*
	H ₂ O	2.26	1175	77	0.000*
	DCM	2.26	739	15	0.000*
Fractionation 2: water (H₂O), ethyl acetate (EtAc) and hexane (HEX)					
ETP (Control = 1678 ± 92 nM/min)	EtEXT	2.26	898	18	0.000*
	H ₂ O	2.26	1072	20	0.000*
	EtAc	2.26	941	21	0.000*
	HEX	2.26	1904	107	0.000*

*Significative difference

Table 3. The anticoagulant activity of *C. sinensis* showed by ETP parameter (calculated as the area under the curve) using high tissue in low concentration as a trigger

Thrombin generation parameters	Tested sample	Concentration (mg/mL)	Mean	SD	p value
Ethanol extract (EtEXT) in different concentrations					
ETP (Control = 1487 ± 99 nM/min)	EtEXT	1.67	732	49	0.000*
	EtEXT	2.26	706	124	0.000*
	EtEXT	2.86	596	76	0.000*
Fractionation 1: water (H₂O) and dichloromethane (DCM)					
ETP (Control = 1678 ± 2 nM/min)	EtEXT	2.26	796	140	0.000*
	H ₂ O	2.26	982	21	0.000*
	DCM	2.26	1148	22	0.000*
Fractionation 2: water (H₂O), ethyl acetate (EtAc) and hexane (HEX)					
ETP (Control = 1678 ± 2 nM/min)	EtEXT	2.26	796	140	0.000*
	H ₂ O	2.26	1255	21	0.000*
	EtAc	2.26	1150	23	0.000*
	HEX	2.26	792	15	0.000*

*Significative difference

**Fig. 1.** Curves showing thrombin formation for control PP and PP added with ethanolic extract (EtEXT) of *C. sinensis* and its fractions elaborated in the fractionation 2: water (H₂O), ethyl acetate (EtAc) and hexane (HEX), employing (a) HTF, and (b) LTF.

3.2. Chemical composition analysis

Screening obtained for the chemical composition performed by TLC and selective reagents demonstrated that EtEXT of *C. sinensis* has presented flavonoids, coumarins and sterols/triterpenes (Table 4), which corroborates the data of scientific literature [4–7]. In addition, water and ethyl acetate fractions showed coumarins, dichloromethane and hexane fractions showed sterols/triterpenes, while flavonoids were found in all fractions.

The UPLC-DAD analysis showed a predominance of polar compounds and

confirmed the existence of flavonoids and coumarins in *C. sinensis* samples, as there were characteristic ultraviolet spectra distributed throughout the chromatogram (Supplementary material 1a) (Mabry, 1970). The fractionations were effective in separating three groups of the substances present in the EtEXT according to polarity, except for the major compound, with retention time (RT) of 7.2 min, which appeared in all fractions. In addition, ultraviolet spectra characteristic of flavonoids also appears in all fractions as well (Supplementary material 1b-d).

Table 4. Qualitative analysis obtained TCL showing the main classes of compounds (special metabolites) of *C. sinensis* ethanolic extract and fractions

Special metabolites	Flavonoids	Phenolics/ Tannins	Coumarins	Sterols/ Triterpenes
<i>Citrus sinensis</i>	+	-	+	+
Fractionation 1: water	+	-	+	-
Fractionation 1: dichloromethane	+	-	-	+
Fractionation 2: water	+	-	+	-
Fractionation 2: ethyl acetate	+	-	+	+
Fractionation 2: hexane	+	-	-	+

4. Discussion

It is well documented that the pharmacotherapy of anticoagulants has some safety limitations, especially concerning interactions [11, 22]. Additionally, interactions between drugs and medicinal plants are recognized as major clinical and economic issues for the health sector [23]. The most commonly reported interaction in adults is the risk of bleeding resulting from the concomitant use of ginkgo, garlic and ginseng with aspirin, WARF, and other antithrombotic drugs [23].

C. sinensis (sweet orange) is largely used by the Brazilian population, mainly as the tea from the leaves to relieve symptoms of anxiety and insomnia [8]. It has been demonstrated that patients using WARF in an anticoagulant clinic in Brazil also use

sweet orange leaves for this purpose, posing an extra risk factor: the potential interaction between herbs and WARF [9, 10]. Thus, identifying possible interactions between sweet orange and anticoagulants is crucial to manage the patients on anticoagulation therapy with more effectiveness. Furthermore, preliminary knowledge about the anticoagulant potential of this plant may open avenues for evaluating *C. sinensis* as a new antithrombotic drug.

4.1. Anticoagulation activity

4.1.1. Conventional coagulometric tests

The combined analysis of PT, aPTT, and PF led to the conclusion that EtEXT of *C. sinensis* inhibited both coagulation pathways in vitro and reduced fibrinogen levels. These tests,

nevertheless, provide information only about the beginning of the coagulation complex process, as the end point happens with just 5% of all the thrombin formed [24–27]. Thus, TGT presents a broader analysis of the hemostatic system over 60 minutes, assessing hemostatic changes with greater sensitivity through the thrombin generated and providing more accurate information about the clotting process as a whole [28–30].

4.1.2. Thrombin generation test

TGT uses the Thrombinoscope software to generate a curve depicting the initiation, propagation, and inhibition of coagulation, demonstrating thrombin formation over 60 minutes. The software calculates five parameters, enabling a comprehensive assessment of blood coagulation [30]. Between the calculated parameters, ETP represents the thrombin produced during the entire coagulation process and is more clinically relevant, showing better the balance between anticoagulant and procoagulant forces [31, 32].

TGT has been applied to study the anticoagulant activity of medicinal plants, showing superiority over conventional coagulometric tests due to its informativeness, robustness, and sensitivity [19, 20]. In the consideration of the different concentrations of tissue factor employed, with HTF, coagulation initiates more quickly, focusing on modifications in the EXTpah. With LTF, coagulation initiation takes longer, showing greater sensitivity to alterations in the intrinsic pathway.

The addition of EtEXT of *C. sinensis* to plasma resulted in a reduction of ETP at all concentrations using both HTF and LTF. This indicates that adding EtEXT to plasma resulted in lower formation of thrombin, in a dose-dependent manner (Table 2, Table 3, and Figure

1). Furthermore, this shows inhibition of the EXTpah, supporting the PT results, and the INTpath, supporting the aPTT results.

Fractions of EtEXT obtained in fractionations 1 and 2 were also tested by TGT. Using HTF, all fractions, except the hexane fraction, significantly reduced ETP values and thrombin formation. In fractionation 1, the DCM fraction was even more effective in reducing ETP than *C. sinensis* EtEXT. In fractionation 2, the EtAc fraction most significantly reduced ETP, but EtEXT still showed higher activity than the fractions.

When using LTF, all fractions significantly reduced ETP and thrombin generation. In fractionation 1, the aqueous fraction was more effective in reducing ETP than the DCM fraction, but not compared to *C. sinensis* EtEXT. In fractionation 2, the HEX fraction most significantly reduced ETP, with activity similar to EtEXT.

Analysis of ETP values suggests that EtEXT of *C. sinensis* and its fractions demonstrated considerable in vitro anticoagulant activity by decreasing thrombin formation, apparently due to the inhibition of both coagulation pathways. These in vitro results suggest a potential interaction between sweet orange and anticoagulants, such as WARF, thereby increasing the risk of bleeding in patients using both concomitantly.

4.2. Fractionation of *C. sinensis*

The biological and pharmacological activities of a plant species directly depend on its constituent substances. Therefore, the chemical composition of the EtEXT and fractions of *C. sinensis* were studied to identify substances referred to the observed activity. The complexity of plants chemistry, and therefore their extracts, often promotes a synergistic effect among the compounds, producing a better therapeutic effect

compared to substances used in isolation [33]. Although classes of chemical substances have been discussed in isolation, it is likely that the phytocomplex (a group of interacting substances) promotes the observed anticoagulant activity in vitro [11, 13].

Analyzing the TLC and UPLC chromatographic profiles for the EtEXT and its fractions revealed that coumarins were detected in the EtEXT and the most polar aqueous fractions (Table 4). Sterols/triterpenes were found in the extract and in the less polar fractions: dichloromethane, ethyl acetate, and hexane (Table 4). Flavonoids were present in the EtEXT and all of the fractions (Table 4) due to their intermediate polarity, which may vary based on the ligands around the basic skeleton. This result was expected as fractionation separates substances according to their affinity for the solvent.

Relating the separation of substances by fractionation with the anticoagulant activity of each fraction, it is possible to speculate on the substances responsible for the observed activity. Considering the extrinsic coagulation pathway, assessed using HTF (Table 2), it is clear that aqueous fractions 1 and 2, rich in more polar compounds such as coumarins and some flavonoids, were active but less so than the ethanol extract. Fractions with medium to low polarity solvents (EtAc and DCM, respectively) were closest to EtEXT in anticoagulant activity in the extrinsic pathway and are rich in flavonoids and sterols/triterpenes. However, the hexane fraction, containing fewer flavonoids and sterols/triterpenes, increased thrombin generation potential. Thus, flavonoids seem to play a crucial part in the anticoagulant activity shown in the extrinsic pathway.

Considering the intrinsic pathway evaluated using LTF (Table 3), the highest activities were

observed in aqueous fractions 1 and the hexane fraction, suggesting the participation of both more and less polar compounds. This result clearly shows that the observed activity for EtEXT in the intrinsic pathway is due to the collective substances present in the extract.

In conclusion, the results indicate that flavonoids are primarily responsible for inhibiting the extrinsic pathway, while the phytocomplex appears to be more active in the intrinsic pathway. Flavonoids appear to be essential in the observed anticoagulant activity in vitro, while coumarins and sterols/triterpenes play a more secondary role. However, a more elaborate fractionation could better identify the specific compounds related to the activity.

4.2.1. Coumarins

Coumarins were identified by TLC, which was also supported by UPLC analyses. They are o-hydrocinnamic acid lactones from the shikimate pathway [34] (Figure 2) and have been associated with various pharmacological properties [35], and both coumarins and furanocoumarins are well distributed in the genus *Citrus* [36].

As WARF is a coumarin derivative, there is speculation that this class possesses anticoagulant effects. However, this effect would not be detected in the tests performed since WARF acts in the liver. Nevertheless, coumarins may inhibit clotting factors similarly to flavonoids, as both classes share a structural portion derived from the shikimate pathway, enabling similar chemical interactions with receptors [19]. Therefore, despite the lack of scientific information supporting the direct effect of coumarins on the coagulation cascade, flavonoids themselves have been extensively studied and implicated in the direct effect on

blood clotting [37] and will be discussed in more detail below.

4.2.2. Flavonoids

Flavonoids are considered to be of mixed biosynthetic origin, formed by three-membered rings [34]. In the chemistry analysis, they are the predominant substances in *C. sinensis* extract and fractions. The major compound in all samples presents a retention time (RT) of 7.2 minutes and a characteristic UV spectrum of a flavanone ($\lambda_{MAX} = 283$ nm referring to band II and low-intensity band I), possibly hesperidin or naringenin (Malby, 1970) [38] (Supplementary Material 1).

This class has significant anticoagulant potential. Flavonoids are known to be anti-inflammatory, as the complex inflammation pathway shares a path with platelet aggregation/coagulation through the arachidonic acid pathway [11, 12]. Flavonoids like luteolin and apigenin have also been associated with antiplatelet activity by inhibiting platelet adhesion, aggregation, and secretion [39, 40], that promotes blood coagulation through the mechanical pathway. Additionally, flavonoids have demonstrated anti-thrombin activity in vitro, and there are studies that evaluated the structure-activity of flavonoids as thrombin inhibitors. Some, like luteolin, have shown antithrombotic activity in vitro and in vivo [41, 37]. Given the large amount of flavonoids in sweet orange and the various possible mechanisms of coagulation inhibition, this class is likely related to the observed in vitro anticoagulant activity.

4.2.3. Sterols/Triterpenes

Sterols and triterpenes are compounds that belong to the class of terpenes and are formed of five-carbon units called isoprenes. Triterpenes contain 30 carbon atoms, and steroids are

modified triterpenes [34]. These compounds are less polar and do not absorb at the wavelength used in UPLC analysis, being detected only by TLC. Nonetheless, there is substantial scientific evidence supporting their participation in the observed anticoagulant activity. Studies indicate that both sterols and triterpenes present anti-inflammatory activity [42, 43]. In vitro, and also in vivo, tests have shown that some triterpenes affect phospholipase A2 and COX-2, which are part of the pathway involving arachidonic acid and thromboxane A2, responsible for platelet aggregation [44, 45]. Triterpenes from *Ilex rotunda* inhibited ADP-induced platelet aggregation in rats [46], while triterpenes from *Melaleuca bracteata* showed antiplatelet and anticoagulant activity in rats [47]. Additionally, a triterpene from *Protiterhus longifolia* increased bleeding time in rats and exhibited anti-inflammatory activity [48].

4.3. Use of *Citrus* in anticoagulated patients

There are no studies that contraindicate the use of *C. sinensis* leaf tea, even in patients on anticoagulants. This is likely because its use is primarily associated with folk medicine, and there are no commercial herbal medicines derived from this plant [8]. However, given the high use of this plant by anticoagulated patients and evidence showing that other *Citrus* species can interact with WARF, it is crucial to be conscious of the potential interaction amongst *C. sinensis* and anticoagulants [13, 16, 17].

Because WARF pharmacotherapy is complex, it is recommended that patients be assisted in anticoagulation clinics, places where clinical management and dose adjustments are performed [49, 50]. However, investigating interactions between drugs and medicinal plants is uncommon, mainly due to a lack of professional training and scientific evidence. Studies

evaluating the anticoagulant activity of certain plants can provide useful information to health professionals in anticoagulation clinics, guiding patients on the non-concomitant use of plants like sweet orange that may interact with anticoagulants [19, 51].

Clinical management of interactions significantly improves the quality of patient treatment. Regardless of the lack of scientific information about herbal-drug interactions, potential interactions may be initially based on in vitro studies, case reports, and the herb's chemical composition [11, 51]. This enables health professionals to be more vigilant about the utilization of herbal medicine with potential interactions with anticoagulants [19, 20, 52].

4.4. Antithrombotic agent: The potential of *C. sinensis*

Thromboembolic disorders are characterized by the formation of clots in blood vessels, which is considered a major cause of cardiovascular diseases. In 1856, Virchow suggested a triad of factors leading to thrombosis including stasis, modifications in the vessel wall, and blood coagulability (Figure 2) [53, 54]. Cardiovascular diseases are, however, preventable through lifestyle changes. Additionally, drugs with anti-inflammatory, antiplatelet, antioxidant, and anticoagulant activities can help prevent thrombus formation [54, 55].




Fig. 2. Scheme demonstrating the possible synergism between *C. sinensis* phytocomplex compounds for antithrombotic activity

As discussed, sweet orange has the chemistry with potential to perform the described activities, primarily due to the large amount of flavonoids in its chemical composition (Figure 2). Coumarins show evidence of anticoagulant activity [19]. Sterols have proven anti-inflammatory activity [42], while triterpenes have demonstrated anti-inflammatory, anticoagulant and antiplatelet activities [44, 47]. Finally, flavonoids are known to present highly antioxidant and anti-inflammatory chemical substances and they also have already been described as antiplatelet and anticoagulant agents [56–58]. Additionally, plant sterols have been shown to lower cholesterol levels, which is beneficial in preventing cardiovascular disease [43].

Given that *C. sinensis* leaves are widely used in tea form and that this plant, according to its chemical composition, has great capability to exert anti-inflammatory, antioxidant, antiplatelet, and anticoagulant activities, further studies could lead to the development of an easily accessible antithrombotic for the population [54, 55]. In vitro models are excellent for guiding research efforts, but they have some limitations, making it essential to conduct studies in humans. Furthermore, it is important to delve deeper into the chemical composition of *C. sinensis* and the relationship of these compounds with each stage of blood coagulation. This study is a first step towards developing new antithrombotics.

5. Conclusion

The integrated analysis of the results demonstrates that the ethanolic extract (EtEXT) of *C. sinensis* leaves exhibited anticoagulant (in vitro) activity by increasing activated partial thromboplastin and prothrombin time, and thrombin formation and also fibrinogen levels. Evidence from the literature, combined with the results of coagulometric tests, supports the theory

that the observed effect may be the result of coagulation factors inhibition. This inhibition is likely a result of the synergistic effects of various chemical substances found in sweet orange, such as flavonoids, coumarins, and sterols/triterpenes. Consequently, the intake of sweet orange by patients undergoing anticoagulation therapy needs to be approached with caution due to the risk of interactions enhancing the anticoagulant activity and increasing the risk of hemorrhage. Additionally, evidence indicates that *C. sinensis* also exhibits antioxidant, anti-inflammatory, and antiplatelet activities. Therefore, further study of these activities could lead to the development of drugs with multiple functions, including antithrombotic properties.

Author contributions

PML, APNM, JMA and RCFD performed the experiments and analyzed its data. PML, AAF, MGC and ROC designed the article; extracted, analyzed data and drafted the manuscript. PML extracted and analyzed data. All authors critically reviewed the manuscript, contributed to its revision, and approved the final version submitted.

Conflict of interest:

The authors declare that there is no conflict of interest.

Acknowledgments

This work was supported by grants from Pró-Reitoria de Pesquisa from Universidade Federal de Minas Gerais, Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG) Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and Laboratório de Farmacognosia e Homeopatia da UFMG (GnosiaH), and by the fellowship for P. M. Leite.

References

1. Favela-Hernández JMJ, González-Santiago O, Ramírez-Cabrera MA, Esquivel-Ferriño PC, Camacho-Corona M del R. Chemistry and Pharmacology of *Citrus sinensis*. *Molecules* 2016; 21: 1-24. doi: 10.3390/molecules21020247.
2. Chaudhari SY, Ruknuddin G and Prajapati P. Ethno medicinal values of *Citrus* genus: A review. *Med. J. Dr DY. Patil. Univ.* 2016; 9(5): 560-565. doi: 10.4103/0975-2870.192146.
3. Mannucci C, Calapai F, Cardia L, Inferrera G, D'Arena G, Pietro Md, Navarra M, Gangemi S, Spagnolo EV and Calapai G. Clinical pharmacology of *Citrus aurantium* and *Citrus sinensis* for the treatment of anxiety. *Evid. Based Complement Altern. Med.* 2018; 2018(2018): 3624094. doi: 10.1155/2018/3624094.
4. Iglesias-Carres L, Mas-Capdevila A, Bravo FI, Aragones G, Muguerza B, Arola-Arnal A. Optimization of a polyphenol extraction method for sweet orange pulp (*Citrus sinensis* L.) to identify phenolic compounds consumed from sweet oranges. *PLoS One* 2019; 14: 1-17. doi: 10.1371/journal.pone.0211267.
5. Haggag E. Flavonoids from the leaves of *Citrus aurantium* (Sour Orange) and *Citrus sinensis* (Sweet Orange). *Asian J. Chem.* 1999; 11(3): 707-714.
6. Kawaii S, Tomono Y, Katase E, Ogawa K, Yano M, Koizumi M, Ito Ch and Furukawa H. Quantitative study of flavonoids in leaves of citrus plants. *J. Agric Food Chem.* 2000; 48(9): 3865-71. doi: 10.1021/jf000100o.
7. Ribeiro AB, Abdejnur PV, Garcia CF, Belini A, Severino VGP, da Silva MF das GF, Fernandes JB, Vieira PC, de Carvalho SA, de Souza AA and Machado MA. Chemical characterization of *Citrus sinensis* grafted on *C. limonia* and the effect of some isolated compounds on the growth of *Xylella fastidiosa*. *J. Agric. Food Chem.* 2008; 56(17): 7815-22. doi: 10.1021/jf801103p.
8. Pimenta F, Tavares N de AC, Neto GC, Alves M, Pimenta MF, Diniz JM, de Medeiros AC and Diniz MM. Pharmacological actions of *Citrus* species. *Citrus Pathol.*, InTech; 2017. doi: 10.5772/66464.
9. Leite PM, de Freitas AA, Mourao A de OM, Martins MAP, Castilho RO. Warfarin safety: A cross-sectional study of the factors associated with the Consumption of Medicinal Plants in a Brazilian anticoagulation clinic. *Am. J. Cardiovasc Drugs* 2018; 18: 231-43. doi: 10.1007/s40256-018-0268-1.
10. Mendonça LP, Oliveira CR, Pinho RAL and Parreira MMA. Consumption of medicinal plants by patients with heart diseases at a pharmacist-managed anticoagulation clinic in Brazil. *Int. J. Clin. Pharm.* 2016; 38(2): 223-7.
11. Leite PM, Martins MAP and Castilho RO. Review on mechanisms and interactions in concomitant use of herbs and warfarin therapy. *Biomed. Pharmacother.* 2016; 83: 14-21. doi: 10.1016/j.biopha.2016.06.012.
12. Leite PM, Martins MAP and Castilho RO. Herbs-warfarin interactions: potential targets and biochemical implications approach. 1st ed. Balti: Editorial Academica Espanola; 2017.
13. Ge B, Zhang Z and Zuo Z. Updates on the clinical evidenced herb-warfarin interactions. *Evidence-Based Complement. Altern. Med.* 2014; 2014(1): 957362. doi: 10.1155/2014/957362.
14. Mallick N, Khan RA, Riaz A and Afroz S. Anticoagulant, antiplatelet and antianemic effects of *Citrus paradisi* (Grape fruit) juice in rabbits. *Pharmacol. Pharm.* 2016; 7(10): 397-406. doi: 10.4236/pp.2016.710047.
15. Brandin H, Myrberg O, Rundlof T, Arvidsson A-K and Brenning G. Adverse effects

by artificial grapefruit seed extract products in patients on warfarin therapy. *Eur. J. Clin. Pharmacol.* 2007; 63: 565-70. doi: 10.1007/s00228-007-0289-1.

16. Mouly S, Lloret-Linares C, Sellier P-O, Sene D and Bergmann J-F. Is the clinical relevance of drug-food and drug-herb interactions limited to grapefruit juice and Saint-John's Wort? *Pharmacol. Res.* 2017; 118: 82-92. doi: 10.1016/j.phrs.2016.09.038.

17. Riaz A, Khan RA, Mirza T, Mustansir T and Ahmed M. In vitro/in vivo effect of *Citrus limon* (L. Burm. f.) juice on blood parameters, coagulation and anticoagulation factors in rabbits. *Pak. J. Pharm. Sci.* 2014; 27: 907-15.

18. Assefa AD, Ko EY, Moon SH and Keum Y-S. Antioxidant and antiplatelet activities of flavonoid-rich fractions of three citrus fruits from Korea. *J. Biotech.* 2016; 6: 109. doi: 10.1007/s13205-016-0424-8.

19. Leite PM, Miranda APN, Amorim JM, Duarte RCF, Bertolucci SK V, Carvalho MdG and Castilho RO. In vitro anticoagulant activity of *Mikania laevigata*: deepening the study of possible interaction between guaco and anticoagulants. *J. Cardiovasc Pharmacol.* 2019; 74(6): 574-83. doi: 10.1097/FJC.0000000000000745.

20. Leite PM, Miranda APN, Amorim JM, Duarte RCF, Faraco AAG, Carvalho MDG and Castilho RO. Thrombin generation test with the calibrated automated thrombogram and anticoagulant activity of *Mentha crispa*. *Blood Coagul Fibrinolysis*. 2020; 31(1): 101-106. doi: 10.1097/MBC.0000000000000859.

21. Wagner H, Bladt S and Zgainski EM. Plant drug analysis: A thin layer chromatography atlas. Springer-Verlag Berlin Heidelberg; 1st ed, 1984.

22. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ, Halperin JL and Lip GYH. Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. *Chest*. 2012; 141(Sup. 2): 531-75. doi: 10.1378/chest.11-2304.

23. Agbabiaka TB, Wider B, Watson LK and Goodman C. Concurrent use of prescription drugs and herbal medicinal products in older adults: A systematic review. *Drugs Aging* 2017; 34: 891-905. doi: 10.1007/s40266-017-0501-7.

24. Hemker HC, Wielders S, Kessels H and Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. *Thromb Haemost.* 1993; 70(4): 617-24.

25. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T and Béguin S. Calibrated automated thrombin generation measurement in clotting plasma. *Pathophysiol Haemost Thromb.* 2003; 33(1): 4-15. doi: 10.1159/000071636.

26. Mann KG. Thrombin formation. *Chest*. 2003; 124(Sup. 3): 4S-10S. doi: 10.1378/chest.124.3_suppl.4s.

27. Wolberg AS. Thrombin generation and fibrin clot structure. *Blood Rev.* 2007; 21(3): 131-42. doi: 10.1016/j.blre.2006.11.001.

28. Duarte RCF, Rios DRA, Rezende SM, Jardim LL, Ferreira CN, Carvalho M das G. Standardization and evaluation of the performance of the thrombin generation test under hypo- and hypercoagulability conditions. *Hematol Transfus Cell Ther.* 2018; 41(3): 244-52. doi: 10.1016/j.htct.2018.08.007.

29. Duarte RCF, Ferreira CN, Rios DRA, Reis HJ Dos, Carvalho M das G. Thrombin generation assays for global evaluation of the hemostatic system: perspectives and limitations. *Rev. Bras. Hematol. Hemoter.* 2017; 39(3): 259-65. doi:

10.1016/j.bjhh.2017.03.009.

30. Duarte RCF, Rios DRA, Leite PM, Alves LC, Magalhaes HPB, Carvalho M das G. Thrombin generation test for evaluating hemostatic effects of Brazilian snake venoms. *Toxicon*. 2019; 163: 36-43. doi: 10.1016/j.toxicon.2019.03.012.

31. Castoldi E and Rosing J. Thrombin generation tests. *Thromb. Res.* 2011; 127(Sup. 3): S21-5. doi: 10.1016/S0049-3848(11)70007-X.

32. Berntorp E and Salvagno GL. Standardization and clinical utility of thrombin-generation assays. *Semin Thromb Hemost.* 2008; 34(7): 670-82. doi: 10.1055/s-0028-1104546.

33. Malongane F, McGaw LJ and Mudau FN. The synergistic potential of various teas, herbs and therapeutic drugs in health improvement: a review. *J. Sci. Food Agric.* 2017; 97(14): 4679-89. doi: 10.1002/jsfa.8472.

34. Dewick PM. Medicinal natural product - a biosynthetic approach 3rd ed. Switzerland: Department of Ecology - Swedish University of Agricultural Science; 2009.

35. Srikrishna D, Godugu C and Dubey PK. A review on pharmacological properties of Coumarins. *Mini. Rev. Med. Chem.* 2018; 18(2): 113-41. doi: 10.2174/1389557516666160801094919.

36. Dugrand-Judek A, Olry A, Hehn A, Costantino G, Ollitrault P, Froelicher Y and Bourgaud F. The distribution of Coumarins and Furanocoumarins in *Citrus* species closely matches *Citrus* phylogeny and reflects the organization of biosynthetic pathways. *PLoS One*. 2015; 10: 1-25. doi: 10.1371/journal.pone.0142757.

37. Liu L, Ma H, Yang N, Tang Y, Guo J, Tao W and Duan J. A series of natural flavonoids as Thrombin inhibitors: structure-activity relationships. *Thromb. Res.* 2010; 126: 365-78. doi: 10.1016/j.thromres.2010.08.006.

38. Mabry TJ, Markham KR and Thomas MB. The systematic identification of flavonoids. New York: Springer; 1970. doi: 10.1007/978-3-642-88458-0.

39. Navarro-Núñez L, Lozano ML, Palomo M, Martínez C, Vicente V, Castillo J, Benavente-García O, Diaz-Ricart M, Escolar G and Rivera J. Apigenin inhibits platelet adhesion and thrombus formation and synergizes with aspirin in the suppression of the arachidonic acid pathway. *J. Agric. Food Chem.* 2008; 56(9): 2970-3976. doi: 10.1021/jf0723209.

40. Khan H, Jawad M, Kamal MA, Baldi A, Xiao J, Nabavi SM and Daglia M. Evidence and prospective of plant derived flavonoids as antiplatelet agents: Strong candidates to be drugs of future. *Food Chem. Toxicol.* 2018; 119: 355-67. doi: 10.1016/j.fct.2018.02.014.

41. Choi J, Kim Y, Shin C, Lee H and Kim S. Antithrombotic activities of Luteolin In vitro and In vivo. *J. Biochem. Mol. Toxicol.* 2015; 29: 552-8. doi: 10.1002/jbt.21726.

42. Vilahur G, Ben-Aicha S, Diaz-Riera E, Badimon L and Padro T. Phytosterols and inflammation. *Curr. Med. Chem.* 2019; 26: 6724-34. doi: 10.2174/0929867325666180622151438.

43. Othman RA and Moghadasian MH. Beyond cholesterol-lowering effects of plant sterols: clinical and experimental evidence of anti-inflammatory properties. *Nutr. Rev.* 2011; 69(7): 371-82. doi: 10.1111/j.1753-4887.2011.00399.x.

44. de Almeida PDO, Boleti AP de A, Rudiger AL, Lourenco GA, da Veiga Junior VF, Lima ES. Anti-inflammatory activity of Triterpenes isolated from *Protium paniculatum* oil-resins. *Evid Based Complement Alternat Med.* 2015; 2015: 293768. doi: 10.1155/2015/293768.

45. Ríos JL, Recio MC, Maáñez S and Giner RM. Natural Triterpenoids as anti-inflammatory agents. *Studies in Natural Products Chemistry* 2000; 22(Part C): 93-143. doi: 10.1016/S1572-

5995(00)80024-1.

46. Yang B, Zhu J-P, Rong L, Jin J, Cao D, Li H, Zhau X-H and Zhao Z-X. Triterpenoids with antiplatelet aggregation activity from *Ilex rotunda*. *Phytochem.* 2018; 145: 179-86. doi: 10.1016/j.phytochem.2017.11.005.

47. Osunsanmi FO, Zaharare GE, Oyinloye BE, Mosa RA, Ikhile MI, Shode FO, Ogunyinka IB and Opoku AR. Antithrombotic, anticoagulant and antiplatelet activity of betulinic acid and 3 β -acetoxybetulinic acid from *Melaleuca bracteata* "Revolution Gold" (Myrtaceae) Muell leaf. *Trop. J. Pharm. Res.* 2018; 17(10): 1983-9. doi: 10.4314/tjpr.v17i10.13.

48. Mosa RA, Ndwendwe T, Cele NF and Opoku AR. Anticoagulant and anti-inflammatory activity of a triterpene from *Protorhus longifolia* stem bark. *J. Med. Plant. Res.* 2015; 9: 613-9. doi: 10.5897/JMPR2015.5740.

49. Witt DM, Clark NP, Kaatz S, Schnurr T and Ansell JE. Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. *J. Thromb. Thrombolysis* 2016; 41: 187-205. doi: 10.1007/s11239-015-1319-y.

50. Ageno W, Gallus AA, Wittkowsky A, Crowther M, Hylek EM and Palareti G. Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. *Chest*. 2012; 141(2): 44-75.

51. Vazquez SR. Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions. *Blood* 2018; 132(21): 2230-9. doi: 10.1182/blood-2018-06-848747.

52. Ha NB, Yang K, Hanigan S, Kurtz B, Dorsch MP, Mak H and Nagel J. Impact of a guideline for the management of antimicrobial/Warfarin interactions in the inpatient setting and across transition of care. *Ann. Pharmacother.* 2016; 50(9): 734-40. doi: 10.1177/1060028016653765.

53. Esmon CT. Basic mechanisms and pathogenesis of venous thrombosis. *Blood. Rev.* 2009; 23(5): 225-9. doi: 10.1016/j.blre.2009.07.002.

54. Kim K and Park K-I. A review of antiplatelet activity of traditional medicinal herbs on integrative medicine studies. *Evid. Based. Complement Alternat Med.* 2019; 2019(1): 7125162. doi: 10.1155/2019/7125162.

55. Esmon CT. Inflammation and thrombosis. *J. Thromb. Haemost.* 2003; 1(7): 1343-8. doi: 10.1046/j.1538-7836.2003.00261.x.

56. Garcia-Lafuente A, Guillamon E, Villares A, Rostagno MA and Martinez JA. Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular disease. *Inflamm. Res.* 2009; 58: 537-52. doi: 10.1007/s00011-009-0037-3.

57. Gomes A, Fernandes E, Lima JLFC, Mira L and Corvo ML. Molecular mechanisms of anti-inflammatory activity mediated by flavonoids. *Curr. Med. Chem.* 2008; 15(16): 1586-605. doi: 10.2174/092986708784911579.

58. Nijveldt R, van Nood E, van Hoorn D, Boelens PG, van Norren K, van Leeuwen PA. Flavonoids: a review of probable mechanisms of action and potential applications. *Am. J. Clin. Nutr.* 2001; 74(4): 418-25. doi: 10.1093/ajcn/74.4.418.

How to cite this article: Leite PM, Nader Miranda AP, Amorim JM, Duarte RCF, Faraco AAG, Carvalho MdG, Castilho RO. *Citrus sinensis*: antithrombotic potential and safety concerns involving possible interactions based on in vitro coagulometric tests. *Journal of Medicinal Plants* 2025; 24(93): 53-67. doi: [10.61882/jmp.24.93.53](https://doi.org/10.61882/jmp.24.93.53)